Home - Catalent Biologics

Contact Us

Catalent Completes Acquisition of RheinCell Therapeutics, Strengthening a Path Towards Industrialization of iPSC-based Therapies

Catalent has Acquired Delphi Genetics and Launches US Plasmid Manufacturing Site

Establishing global pDNA development and manufacturing capabilities to support cell and gene therapy programs from preclinical through to commercialization

Catalent on Track to Produce Over One Billion Doses of Covid-19 Vaccines and Therapies

Working on 80+ compounds for 60+ customers across our global network

Developing Biologic Drugs is Science.

Accelerating Advanced Treatments & Vaccines is Art.

Catalent Completes Acquisition of RheinCell Therapeutics, Strengthening a Path Towards Industrialization of iPSC-based Therapies

Catalent has Acquired Delphi Genetics and Launches US Plasmid Manufacturing Site

Establishing global pDNA development and manufacturing capabilities to support cell and gene therapy programs from preclinical through to commercialization

Catalent on Track to Produce Over One Billion Doses of Covid-19 Vaccines and Therapies

Working on 80+ compounds for 60+ customers across our global network

Developing Biologic Drugs is Science.

Accelerating Advanced Treatments & Vaccines is Art.

How can we work together

BIOLOGICS DEVELOPMENT

Latest News

Catalent Biologics Launches New GPEx® Lightning Cell Line Expression Technology to Shorten Drug Substance Development Timelines by up to Three Months

CATALENT RESPONDS TO THE GLOBAL COVID-19 OUTBREAK

We are taking decisive action to minimize the impact of the COVID-19 pandemic on our employees, partners, customers, and their patients.

With our advanced technologies and expertise in both autologous and allogeneic development and manufacturing, Catalent is your full-service partner for CAR-T immunotherapies and beyond.

Our Gene Therapy team combines leading expertise in viral vector technology and scale-up with state-of-the-art CGMP facilities, including dedicated plasmid DNA manufacturing sites and our FDA approved commercial facility.

STRATEGIES TO ACHIEVE SUCCESSFUL COMMERCIAL APPROVAL & LAUNCH

Experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the successful launch and approval of a biologic.

BIOLOGICS NETWORK

Our network of biologics sites provides an integrated approach to get medicines to your patients faster anywhere in the world.

Catalent is growing in Biologics and is making significant investments in people in this area. Explore global career opportunities with our Biologics team.</p> <p>

EXPERT CONTENT

Advances in Analytical Technology for Biopharmaceuticals

Prefilled Syringes & Parenteral Manufacturing

Accelerating Method Transfer: Effective Automation Of Biological Assays